Hepatitis B: what every marker on your blood test means

How common is hepatitis B in the Arab world?

Hepatitis B virus (HBV) infects liver cells and can cause either acute infection, which resolves on its own in most adults, or chronic infection lasting more than six months, which carries long-term risks of cirrhosis and liver cancer. A comprehensive review published in the Arab Journal of Gastroenterology in 2013 found that carrier rates in the Arab world vary widely by country but reach significant levels in parts of Egypt, Iraq, Libya, Sudan and the Gulf. The introduction of childhood vaccination programmes in the 1990s has reduced infection rates substantially in younger generations, but older adults who were never vaccinated carry a higher burden of chronic infection.

A 2016 review in the Eastern Mediterranean Health Journal examining hepatitis B and C in Syria found that conflict and displacement had disrupted vaccination programmes and blood safety systems, underlining how a preventable infection becomes resurgent when public health infrastructure is weakened. Understanding the regional picture matters because it shapes how seriously you and your doctor should treat an abnormal test result or an exposure event.

Hepatitis B is not transmitted by casual social contact. You cannot catch it by sharing meals, hugging, shaking hands, coughing, sneezing or swimming in the same pool. The virus spreads through blood-to-blood contact, including unsterile tattooing and piercing equipment, shared razors and needles, unprotected sexual contact, and from an infected mother to her baby during delivery. This distinction is important because stigma and social avoidance harm people with hepatitis B without any medical basis.

What does each marker on the hepatitis B test mean?

A hepatitis B blood panel is one of the most commonly misread lab results because it uses abbreviations that look similar but mean very different things. Understanding what each marker tells you is the first step toward knowing your status and what to do next.

HBsAg stands for hepatitis B surface antigen. Its presence in your blood means the virus is currently in your body. If it remains positive for more than six months, you have chronic hepatitis B. A negative HBsAg means the virus is not currently detected. Anti-HBs is the protective antibody. A positive Anti-HBs at a sufficient concentration means you are immune, either from vaccination or from having recovered naturally from a past infection. This is the result you want to see.

Anti-HBc is the antibody that forms after actual infection (not vaccination). Its presence, especially alongside a negative HBsAg and positive Anti-HBs, usually means a past infection that resolved. HBeAg indicates active viral replication. When it is positive, the virus is multiplying actively and the person is significantly more infectious. When it is absent in someone who is HBsAg positive, the virus is typically less active, though monitoring is still required. HBV DNA measures the actual quantity of virus in the blood. This is the most important number when a doctor is deciding whether to start antiviral treatment.

What is the difference between a healthy carrier and active chronic hepatitis B?

Not everyone who tests positive for HBsAg needs immediate drug treatment. There is an important clinical distinction between a healthy carrier, also called the inactive phase, and active chronic hepatitis B. A healthy carrier is someone in whom the immune system is controlling the virus: HBV DNA levels are very low or undetectable, liver enzymes are normal, and there is minimal liver inflammation. People in this phase can live normally for decades without progression to cirrhosis.

Active chronic hepatitis B is different. HBV DNA is high, liver enzymes are elevated, and there is ongoing inflammation that can steadily damage the liver if left untreated. This is the phase where antiviral treatment substantially reduces the risk of long-term harm. Between these two states there is also a phase called the immune active phase, where the virus and the immune system are in conflict. This phase needs careful monitoring and often treatment.

A landmark study published in The Lancet Gastroenterology and Hepatology in 2019 documented that infants infected at birth progress to chronic hepatitis B in up to 90 percent of cases, compared with fewer than 5 percent of adults who acquire the infection for the first time. This difference explains why birth-dose vaccination is so critical: an infection caught at the most vulnerable moment becomes a lifelong condition in the vast majority of cases.

Can hepatitis B be treated?

A complete cure that eliminates the virus from the body remains beyond current treatment in most cases, but the available antivirals can suppress viral replication to undetectable levels, which effectively stops liver damage and sharply reduces the risk of cirrhosis and liver cancer. The most widely used agents today are tenofovir (in two forms: TDF and TAF) and entecavir. These are taken as a single daily tablet and are generally well tolerated with few side effects.

The decision to start treatment is based on a combination of HBV DNA level, liver enzyme results, liver stiffness measured by ultrasound or Fibroscan, and the patient's age and family history. Not every person with chronic hepatitis B needs treatment immediately. Those in the healthy carrier phase with consistently normal enzymes and low viral loads are typically monitored every six months rather than treated.

Treatment, when needed, is often long-term. In some people with a specific pattern of surface antigen loss, it may eventually be possible to stop safely. For most, treatment continues indefinitely. The goal throughout is protecting the liver, which is the organ most at risk from decades of viral activity. Starting treatment before significant fibrosis develops produces the best outcomes.

Why vaccination matters even for adults who missed it as children

The hepatitis B vaccine is one of the most effective vaccines ever developed. Three doses given over six months produce protective antibody levels in over 95 percent of healthy adults. The vaccine has been part of childhood immunisation schedules across Arab countries since the late 1990s, meaning most people born after 2000 are likely vaccinated. However, those born before routine vaccination began, and those whose vaccination records are uncertain, may not be protected.

A 2025 study in Scientific Reports examining hepatitis B knowledge and stigma in the UAE found that awareness of prevention, including vaccination, remained lower than ideal in several population groups. The researchers noted that stigma associated with the diagnosis was a barrier to both testing and vaccination, as people feared being labelled. This is a preventable outcome: vaccination eliminates the risk entirely, and testing without stigma allows early intervention.

Adults in higher-risk groups should be vaccinated if they have no documented history of vaccination and test negative for all hepatitis B markers. This includes healthcare workers, people sharing living space with a chronic carrier, and those with multiple sexual partners. If you have been exposed to potentially infected blood or body fluids very recently, go to a hospital within 24 hours: an emergency injection of hepatitis B immunoglobulin (HBIG) combined with the first vaccine dose can prevent infection from taking hold.

Protecting your family when someone at home carries the virus

When a family member has chronic hepatitis B, the practical response is to test all household members and vaccinate those who are not already immune. Routine daily contact, including sharing meals, using the same bathroom and close physical affection, poses no meaningful transmission risk. The virus does not live on surfaces and is not transmitted through air.

A 2021 review in the World Journal of Gastroenterology confirmed that mother-to-child transmission at birth, which is the most efficient route, can be prevented by giving the newborn both the hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) within twelve hours of delivery. This intervention reduces transmission risk by more than 90 percent even when the mother has a high viral load. Any woman who knows she has hepatitis B should inform her obstetric team well before delivery so the birth-dose plan is in place.

Sharing razors, nail scissors or toothbrushes with anyone, infected or not, is a poor hygiene habit because these items can carry invisible traces of blood. Avoiding this practice is reasonable regardless of hepatitis B status. Beyond this, daily home life requires no modification. The most harmful consequence of misunderstanding transmission is the social isolation that carriers sometimes experience from their own families.

Warning signs that need urgent medical attention

Most people with chronic hepatitis B feel well for years. When the liver begins to struggle, symptoms develop gradually and can be subtle at first. Fatigue that is out of proportion to activity level, a persistent dull ache under the right rib cage, and a feeling of abdominal fullness can all indicate worsening liver function and should prompt a check-up.

Jaundice, the yellowing of the skin and the whites of the eyes, is a signal that the liver is unable to process bilirubin normally and needs assessment the same day. Abdominal swelling from fluid accumulation (ascites) and unexpected bleeding or bruising indicate that liver function is severely compromised. These are not symptoms to wait and watch.

Using Sihtak to stay on top of your monitoring

Living with chronic hepatitis B means a commitment to every-six-month check-ups for the rest of your life. Many people find it difficult to remember when their last ultrasound was, what their ALT was six months ago, or whether their AFP has been stable or creeping upward. The Sihtak app lets you log each set of results as they come in, plot the trend over time, and carry your history into any new clinic or consultation.

When results from multiple years are visible side by side, your doctor can make much faster and more confident decisions about whether to start treatment, adjust it, or continue monitoring. That clarity is worth more than any single test result in isolation.

Sources

• Gasim GI: Hepatitis B virus in the Arab world: where do we stand?, Arab journal of gastroenterology, 2013
• Bashour H, Muhjazi G: Hepatitis B and C in the Syrian Arab Republic: a review, Eastern Mediterranean health journal, 2016
• Veronese P, Dodi I, Esposito S et al: Prevention of vertical transmission of hepatitis B virus infection, World journal of gastroenterology, 2021
• Indolfi G, Easterbrook P, Dusheiko G et al: Hepatitis B virus infection in children and adolescents, The lancet. Gastroenterology and hepatology, 2019
• Barqawi HJ, Samara KA, Al Ansari MM et al: Hepatitis B knowledge and stigma in the United Arab Emirates, Scientific reports, 2025
• World Health Organization: Hepatitis B fact sheet, WHO, 2024